Companies / Avalo Therapeutics, Inc. / Activity
Activity — Avalo Therapeutics, Inc.
30 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle Mittie Executive | Sell | Common Stock | $411.6K | -25K -87.56% | 3,622 <0.01% of shares | medium |
| Mar 28, 2026 | Neil Garry Arthur CEO | Other | Common Stock | $304.1K | -22K -19.55% | 90,114 0.17% of shares | low |
| Mar 16, 2026 | Doyle Mittie Executive | Exercise | Common Stock | $246.7K | +20K +538.38% | 23,122 0.04% of shares | low |
| Mar 28, 2026 | Sullivan Christopher Ryan Executive | Other | Common Stock | $114.5K | -8K -19.84% | 33,297 0.06% of shares | low |
| Mar 16, 2026 | Doyle Mittie Executive | Exercise | Common Stock | $48.2K | +6K +25.91% | 29,114 0.05% of shares | low |
| Jun 2, 2026 | Kaplan Gilla Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,100 0.04% of shares | low |
| Mar 28, 2026 | Sullivan Christopher Ryan Executive | Exercise | Restricted Stock Units | — | -24K -50.00% | 24,200 0.05% of shares | low |
| Mar 28, 2026 | Sullivan Christopher Ryan Executive | Exercise | Common Stock | — | +24K +139.58% | 41,538 0.08% of shares | low |
| Feb 26, 2026 | Sullivan Christopher Ryan Executive | Grant | Stock Option (Right to Buy) | — | +105K | 105,000 0.20% of shares | low |
| Mar 28, 2026 | Chan Mitchell Director | Exercise | Restricted Stock Units | — | -3K -49.99% | 3,167 <0.01% of shares | low |
| Mar 28, 2026 | Chan Mitchell Director | Exercise | Common Stock | — | +3K +99.97% | 6,333 0.01% of shares | low |
| Dec 31, 2025 | Jain Rita Director | Grant | Stock Option (Right to Buy) | — | +1K | 1,043 <0.01% of shares | low |
| Feb 26, 2026 | Varki Paul Executive | Grant | Stock Option (Right to Buy) | — | +80K | 80,000 0.15% of shares | low |
| Dec 31, 2025 | Lind Kevin Robert Director | Grant | Stock Option (Right to Buy) | — | +848 | 848 <0.01% of shares | low |
| Mar 28, 2026 | Neil Garry Arthur CEO | Exercise | Restricted Stock Units | — | -65K -50.00% | 64,867 0.12% of shares | low |
| Mar 28, 2026 | Neil Garry Arthur CEO | Exercise | Common Stock | — | +65K +137.60% | 112,006 0.21% of shares | low |
| Feb 26, 2026 | Neil Garry Arthur CEO | Grant | Stock Option (Right to Buy) | — | +286K | 286,000 0.53% of shares | low |
| Mar 28, 2026 | Truex Samantha Director | Exercise | Restricted Stock Units | — | -3K -49.99% | 3,167 <0.01% of shares | low |
| Mar 28, 2026 | Truex Samantha Director | Exercise | Common Stock | — | +3K +99.97% | 6,333 0.01% of shares | low |
| Mar 28, 2026 | Goldman Jonathan Director | Exercise | Restricted Stock Units | — | -3K -49.99% | 3,167 <0.01% of shares | low |
| Mar 28, 2026 | Goldman Jonathan Director | Exercise | Common Stock | — | +3K | 3,166 <0.01% of shares | low |
| Mar 28, 2026 | Kantoff Aaron Director | Exercise | Restricted Stock Units | — | -3K -49.99% | 3,167 <0.01% of shares | low |
| Mar 28, 2026 | Kantoff Aaron Director | Exercise | Common Stock | — | +3K +99.97% | 6,333 0.01% of shares | low |
| Mar 28, 2026 | Kaplan Gilla Director | Exercise | Restricted Stock Units | — | -3K -49.99% | 3,167 <0.01% of shares | low |
| Mar 28, 2026 | Kaplan Gilla Director | Exercise | Common Stock | — | +3K +99.97% | 6,333 0.01% of shares | low |
| Mar 16, 2026 | Doyle Mittie Executive | Exercise | Stock Option (Right to Buy) | — | -6K -3.87% | 149,008 0.28% of shares | low |
| Mar 16, 2026 | Doyle Mittie Executive | Exercise | Stock Option (Right to Buy) | — | -20K -8.33% | 214,500 0.40% of shares | low |
| Feb 26, 2026 | Boyd Taylor Executive | Grant | Stock Option (Right to Buy) | — | +95K | 95,000 0.18% of shares | low |
| Feb 26, 2026 | Riley Jennifer Executive | Grant | Stock Option (Right to Buy) | — | +95K | 95,000 0.18% of shares | low |
| Feb 26, 2026 | Doyle Mittie Executive | Grant | Stock Option (Right to Buy) | — | +105K | 105,000 0.20% of shares | low |